TheraCIM hR3

3 trials

Sponsors

Center of Molecular Immunology(CIM), Center of Molecular Immunology (CIM)

Conditions

Hepatocellular carcinomaNon-surgical malignant esophagus tumors.Primary malignant colon and breast lesion and metastatic liver lesions.

Phase 1

hR3 MAb in combination with chemo-embolization in hepatocellular carcinoma.

RecruitingRPCEC00000022

Center of Molecular Immunology (CIM)Hepatocellular carcinoma

Start: 2007-01-02Target: 15Updated: 2026-03-30

Phase 2

h-R3 MAb combined with radio chemotherapy to treat non-surgical esophagus tumors of epithelial origin.

Active, not recruitingRPCEC00000014

Center of Molecular Immunology(CIM)Non-surgical malignant esophagus tumors.

Start: 2005-12-14Target: 68Updated: 2026-03-30

hR3 monoclonal antibody combined with chemoembolization in mestatatic liver treatment.

RecruitingRPCEC00000023

Center of Molecular Immunology (CIM)Primary malignant colon and breast lesion and metastatic liver lesions.

Start: 2006-09-29Target: 15Updated: 2026-03-30